553 The influence of {CYP2D6} and {CYP3A5} pharmacogenetics on pharmacokinetics of tamoxifen and its metabolites in Asian breast cancer patients

B. Chowbay; J.S.L. Lim; O. Singh; R.C.H. Ng; N.S. Wong; E.J.D. Lee

首页> 外文期刊>European Journal of Cancer Supplements >553 The influence of {CYP2D6} and {CYP3A5} pharmacogenetics on pharmacokinetics of tamoxifen and its metabolites in Asian breast cancer patients

【24h】

553 The influence of {CYP2D6} and {CYP3A5} pharmacogenetics on pharmacokinetics of tamoxifen and its metabolites in Asian breast cancer patients

机译：553 {CYP2D6 }和 {CYP3A5 }药物遗传学对他莫昔芬及其代谢物在亚洲乳腺癌患者中药代动力学的影响

获取原文

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2010年第7期|共页
作者
B. Chowbay; J.S.L. Lim; O. Singh; R.C.H. Ng; N.S. Wong; E.J.D. Lee;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients. [J] . Lim JS, Chen XA, Singh O, British Journal of Clinical Pharmacology . 2011,第5期

机译：CYP2D6，CYP3A5，CYP2C9和CYP2C19多态性对亚洲乳腺癌患者他莫昔芬药代动力学的影响。
2. Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients [J] . Joanne S. L. Lim, Xiang A. Chen, Onkar Singh, British Journal of Clinical Pharmacology . 2011,第5期

机译：CYP2D6，CYP3A5，CYP2C9和CYP2C19多态性对亚洲乳腺癌患者他莫昔芬药代动力学的影响
3. Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients [J] . Joanne S. L. Lim, Xiang A. Chen, Onkar Singh, British journal of clinical pharmacology . 2011,第5期

机译：CYP2D6，CYP3A5，CYP2C9和CYP2C19基因多态性对亚洲乳腺癌患者他莫昔芬药代动力学的影响
4. IMPACT OF CYP2D6 GENETIC POLYMORPHISM ON THE PHARMACOKINETICS OF TRAMADOL AND ITS THREE MAIN METABOLITES IN KOREANS [C] . Jung-Woo Bae, Sooyeun Lee, Kyung-Soo Chun, International Mass Spectrometry Conference . 2018

机译：CYP2D6遗传多态性对曲马多及其三种主要代谢产物的影响
5. Melatonin-Tamoxifen Drug Conjugates as Breast Cancer Drugs: Pharmacological Evaluation in Phenotypically Diverse Breast Cancer Models and Pharmacokinetic Assessment in Liver Microsome and Female Mouse Models [D] . Hasan, Mahmud. 2020

机译：褪黑激素 - 西昔芬药物缀合物作为乳腺癌药物：在肝微粒和女性小鼠模型中表型多种乳腺癌模型和药代动力学评估的药理评估
6. Impact of CYP2D6 CYP3A5 CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients [O] . Joanne S L Lim, Xiang A Chen, Onkar Singh, 2011

机译：CYP2D6CYP3A5CYP2C9和CYP2C19多态性对亚洲乳腺癌患者他莫昔芬药代动力学的影响
7. Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients [O] . Lim, Joanne S L, Chen, Xiang A, Singh, Onkar, 2011

机译：CYP2D6，CYP3A5，CYP2C9和CYP2C19多态性对他莫昔芬药代动力学在亚洲乳腺癌患者中的影响

553 The influence of {CYP2D6} and {CYP3A5} pharmacogenetics on pharmacokinetics of tamoxifen and its metabolites in Asian breast cancer patients

著录项

引文网络

相似文献

相关主题

期刊订阅